<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> is most frequently caused by deletion of the maternally derived chromosome 15q11-q13 region, which includes not only the causative UBE3A gene, but also the beta(3)-alpha(5)-gamma(3) <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor subunit gene cluster </plain></SENT>
<SENT sid="1" pm="."><plain>GABAergic dysfunction has been hypothesized to contribute to the occurrence of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and cognitive and behavioral impairments in this condition </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, analysis of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor subunit expression and pharmacology was performed in cerebral cortex from four subjects with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> and compared to that from control tissue </plain></SENT>
<SENT sid="3" pm="."><plain>The membrane fraction of frozen postmortem neocortical tissue was isolated and subjected to quantitative Western blot analysis </plain></SENT>
<SENT sid="4" pm="."><plain>The ratios of beta(3)/beta(2) and alpha(5)/alpha(1) subunit protein expression in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> cortex were significantly decreased when compared with controls </plain></SENT>
<SENT sid="5" pm="."><plain>An additional membrane fraction was injected into Xenopus oocytes, resulting in incorporation of the brain membrane vesicles with their associated receptors into the oocyte cellular membrane </plain></SENT>
<SENT sid="6" pm="."><plain>Two-electrode voltage-clamp analysis of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor currents was then performed </plain></SENT>
<SENT sid="7" pm="."><plain>Studies of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor pharmacology in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> cortex revealed increased current enhancement by the alpha(1)-selective <z:chebi fb="13" ids="22720">benzodiazepine</z:chebi>-site <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="10125">zolpidem</z:chebi> and by the <z:chebi fb="8" ids="29745">barbiturate</z:chebi> <z:chebi fb="1" ids="8069">phenobarbital</z:chebi>, while sensitivity to current inhibition by zinc was decreased </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor affinity and modulation by neurosteroids were unchanged </plain></SENT>
<SENT sid="9" pm="."><plain>This shift in <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor subunit expression and pharmacology in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> is consistent with impaired extrasynaptic but intact to augmented synaptic cortical GABAergic inhibition, which could contribute to the <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e>, behavioral, and cognitive phenotypes of the disorder </plain></SENT>
</text></document>